Increased expression of insulin-like growth factor I in skin in amyotrophic lateral sclerosis

Seiitsu Ono, Jianguo Hu, Takashi Imai, Natsue Shimizu, Mayumi Tsumura, Hachiro Nakagawa

Abstract

Objectives—Insulin-like growth factor I (IGF-I) has potent effects on motor neuron survival and is being studied as a possible therapeutic agent for ALS. However, little is known concerning IGF-I in the skin of patients with amyotrophic lateral sclerosis (ALS). The aim was to evaluate IGF-I immunoreactivity of skin in patients with ALS.

Methods—IGF-I immunoreactivity of skin from 18 patients with ALS and 16 controls was examined.

Results—IGF-I immunoreactivity was markedly positive in the epidermis and dermal blood vessels and glands and was moderately positive in the reticular dermis in all patients with ALS. On the other hand, the epidermis and dermal blood vessels and glands and the reticular dermis showed a weak IGF-I immunoreactivity in controls. The optical density for IGF-I immunoreactivity of the epidermis and dermal blood vessels and glands, and the reticular dermis in patients with ALS was significantly higher than in diseased controls, and was significantly increased with duration of illness.

Conclusions—These data suggest that a metabolic alteration of IGF-I may take place in the skin of patients with ALS.

Keywords: amyotrophic lateral sclerosis; insulin-like growth factor I; immunohistochemistry

Sporadic amyotrophic lateral sclerosis (ALS) is an idiopathic and progressive neurodegenerative disorder of unknown aetiology primarily characterised by loss of motor neurons in the cerebral cortex and spinal cord.1 There are many hypotheses about the cause of this disease. One general theory of the underlying cause of ALS is that motor neurons lack crucially needed trophic factors, resulting in neuronal degeneration, cell death, and atrophy of target muscles.2

Insulin-like growth factor I (IGF-I) is a naturally occurring single chain polypeptide consisting of 70 amino acids. It is expressed by various tissues including skeletal muscle and the CNS. Receptors for IGF-I are found throughout the body, including spinal motor neurons, muscle, and brain. There has been recent evidence supporting the hypothesis of neurotrophic effects of IGF-I. It induces brain growth and myelination in transgenic mice,2 stimulates the regeneration of lesioned peripheral nerves,3 promotes survival of motor neurons in vitro,4 induces marked collateral sprouting of intramuscular nerve fibres,5 and increases myelination with inhibition of demyelination in cultured organotypic nerve tissues.6 It has been also shown to reduce spinal cord motor neuron death in vitro, to lower programmed death of motor neurons during the development of the embryonic chicken, and to increase motor neuronal sprouting in degenerated muscles.7 For these reasons, IGF-I may be involved, directly or indirectly, in the aetiology of various neurodegenerative disorders and, therefore, might be of therapeutic value for these diseases.

In 1981 Appel7 put forward the hypothesis that the reduced availability of neurotrophic factors might lead to degeneration of motor neurons in motor neuron diseases. Since then it has become apparent that several neurotrophic agents, such as IGF-I, may act during development and also during conditions of cell degeneration to support the survival of motor neurons.11 IGF-I increases muscle strength and fibre size in the wobbler mouse model of motor neuron disease.12 These findings may have important implications for the potential of IGF-I as a therapeutic agent for the treatment of ALS. Although the role of neurotrophic factors in the pathogenesis of human motor neuron diseases remains unclear, the availability of IGF-I as a recombinant protein has allowed its study as an experimental therapy for motor neuron disease, including ALS.13 14 Recently, two randomised double blind, placebo controlled clinical trials that used recombinant human IGF-I (rhIGF-I) were conducted in patients with mild to moderate ALS.13 14 Compared with the placebo, 0.1 mg/kg/day rhIGF-I significantly attenuated the progression of ALS.13 These studies merit emphasis that IGF-I is biologically and structurally distinct from ciliary neurotrophic factor and brain derived neurotrophic factor.15

However little is known about IGF-I in the skin of patients with ALS. Because IGF-I is being studied as a possible therapeutic agent for ALS, a disorder in which numerous alterations are seen in the skin as well as in the nervous system, we have examined IGF-I immunoreactivity in the skin of patients with ALS.

Patients and methods

Patients

Our subjects were 18 patients with ALS (mean age (SD) 61.3 (7.4) years; range, 45–68 years; 12 men and six women) and 16 controls with other neurological or muscular diseases (mean age (SD) 57.2 (9.6) years; range, 48–72 years; 11 men and five women). The diagnosis of
ALS was based on a detailed history and physical examination, extensive hematological, biochemical, electrophysiological, and radiological testing, and muscle biopsy. The patients with ALS all had progressive weakness and muscular atrophy associated with signs of both upper and lower motor neuron dysfunction with no sensory abnormalities, clear evidence of progression, normal nerve conduction velocities and late responses, and electrophysiological evidence of diffuse denervation. The diagnosis of ALS was made according to the El Escorial criteria of the World Federation of Neurology and all patients with ALS had clinically definite ALS. Twelve patients with ALS had bulbar symptoms, which were deemed to be severe in five. The diagnoses in control subjects were chronic inflammatory demyelinating polyradiculoneuropathy (two), polymyositis (two), Alzheimer’s disease (one), periarthritis nodosa (one), Parkinson’s disease (two), spino-cerebellar degeneration (two), neurogenic amyotrophy (two), multiple sclerosis (one), myasthenia gravis (one), mitochondrial encephalomyopathy (one), and progressive supranuclear palsy (one). The age and sex distribution of the two groups were comparable.

Five patients with ALS with moderate to severe bulbar symptoms and five control patients (Alzheimer’s disease, Parkinson’s disease, spinocerebellar degeneration, mitochondrial encephalomyopathy, and progressive supranuclear palsy in one patient each) incapable of self feeding because of dysphagia or the difficulty in taking food and water used tube feeding or a feeding gastrostomy. There were no differences in diet between these patients with ALS and the controls. The duration of the tube feeding was 0.8 (SD 0.2) years in patients with ALS and 0.7 (SD 0.3) years in control patients. Both patients with ALS and controls who required tube feeding or a feeding gastrostomy received between 1500 and 1800 calories/day, and had a good nutritional status. Height (m) and weight (kg) were recorded and (wt/m²) was calculated.

There was no significant difference in the body mass index between patients with ALS (19.5 (SD 4.5)) and control subjects (20.7 (SD 4.8)). Informed consent was obtained from all patients with ALS and all the control patients.

Functional ability in patients with ALS and controls was measured using the Barthel disability scale. The total average score was 9.3 (range, 4.0–14.0) in patients with ALS and 10.4 (range, 3.0–15.0) in control patients. The average score for feeding was 0.86 in patients with ALS and 1.13 in controls. The two groups were similar in both the total average score and the average score for feeding in the Barthel index.

Tissue Processing

Two 3 mm biopsy specimens of skin overlying the left biceps from all patients with ALS and all controls were obtained after local anaesthesia with 1% procaine. Biopsy sites were free of atrophic or hypertrophic scars, recent bruises, or induration. Special care was taken to minimise stress on the tissue when performing the biopsy. Each specimen was fixed in 4% formaldehyde solution. Observations were made in all cases by three examiners who had no information on the clinical history and condition of the patient providing the skin specimen. All samples were fixed for 48 hours in 10% formalin containing 1% cetylpyridinium chloride, then embedded in paraffin.

Immunohistochemistry

Sections 6 µm thick from each paraffin block were deparaffinised with xylene and hydrated in ethanol and phosphate buffered saline (PBS, pH 7.4), and then treated with 0.3% hydrogen peroxide in anhydrous methanol for 60 minutes. After treatment with trypsin, the sections...
were incubated with rabbit serum for 20 minutes to block the non-specific binding of antibodies. The sections were reacted with primary antibodies and stained for immunoreactivity by the avidin-biotin peroxidase complex (ABC) method, using ABC kits (Vector Laboratories, Burlingame, CA, USA). Monoclonal antibody against IGF-I was purchased from R and D systems (Minneapolis, MN, USA) and diluted 1:75 with PBS (pH 7.2). Consecutive sections were also stained with mouse serum in place of primary antibody to verify the specificity of the staining. After slight counterstaining with haematoxylin, samples were mounted and IGF-I immunoreactivity was assessed in relation to corresponding control haematoxylin and cosin stained serial sections.

RELATIVE OPTICAL DENSITY MEASUREMENT
From each patient, about 50 randomly selected sections obtained from the paraffin blocks were studied. The images of the sections were scanned by Scan Jet 4c (Hewlett Packard, Tokyo, Japan) and Adobe Photoshop software version 4.0J. A densitometric analysis was performed using KS100 image software version 2.0. Total IGF-I content was obtained by delimiting the positive areas for immunolabeling on each section, determining their range of grey levels, and marking the areas to be analysed. After that, they were measured and evaluated by an image analysis program. The integrated optical density (IOD) was the parameter tested and the amount of IGF-I for each patient was represented by the total of the different measurements taken. All the sections were analysed by the same examiner who had no information on the clinical history and condition of the patient providing the skin specimen.

STATISTICAL ANALYSIS
Statistical comparisons were made by two tailed Student's t test with p<0.05 as the significance level. Correlation coefficients were calculated by the least squares method. Results are expressed as the mean (SD).

Figure 2 Optical density measurements of IGF-I immunoreactivity in the skin in patients with ALS and in controls. (A) The density for IGF-I immunoreactivity in the epidermis and dermal blood vessels and glands was significantly higher (p<0.001) in patients with ALS than in controls. Bars show mean (SD). (B) The density for IGF-I immunoreactivity in the reticular dermis was significantly higher (p<0.001) in patients with ALS than in controls. Bars show mean (SD).

Figure 3 Correlation of duration of illness with the optical density for IGF-I immunoreactivity in patients with ALS. (A) There was a significant positive relation (r=0.75, p<0.001) between the density of immunoreactivity in the epidermis and dermal blood vessels and glands and duration of illness. (B) There was a significant positive relation (r=0.72, p<0.001) between the density of immunoreactivity in the reticular dermis and duration of illness.
Ono, Hu, Imai, et al

The most significant finding in the skin of patients with ALS in our study was the increased IGF-I immunoreactivity, which was even more significant in patients with ALS with a longer duration of disease. In addition, weakly stained diseased controls remained unchanged even after the immunohistochemical procedure was modified to optimally retrieve lost antigens. Thirteen patients with ALS and seven controls had marked muscular atrophy beneath the biopsied skin, and seven patients with ALS and five controls were bedridden over a period of 1 year. Thus the skin abnormalities in patients with ALS were not secondary changes as a consequence of weight loss, muscular atrophy, loss of active movement in the biopsied limb, or bedridden state, indicating that the increased IGF-I immunoreactivity of skin does not reflect nutritional status or activity dependent skin remodelling. Thus the increase in IGF-I immunoreactivity of skin in ALS might indicate an augmentation of IGF-I content due to reduced degradation, increased synthesis, or increased binding of circulating IGF-I by skin components.

The role of IGF-I in human skin is still not completely understood. Insulin-like growth factor I stimulates the synthesis and deposition of various extracellular matrix proteins important in wound healing\(^{26}\) and may play a significant part in both the early and late wound environments.\(^{19}\) It is expressed locally in response to tissue injury and presumed to be an essential part of the wound healing machinery.\(^{22-24}\) Further, IGF-I has been shown to enhance healing when added exogenously to healing wounds.\(^{25}\) Therefore, it may be advantageous to augment growth factor concentrations to achieve accelerated normal healing or to correct impaired healing. These findings imply that the increased IGF-I immunoreactivity of skin in ALS may be related to the absence of bedsore formation even in the terminal stages of ALS.\(^{22}\)

Insulin-like growth factor I selectively stimulates gene expression of type III collagen in the granulation tissue but not type I collagen.\(^{26}\) Spanheimer et al.\(^{26}\) have presented data showing a strong relation between IGF-I concentrations and changes in collagen biosynthesis in rats in response to short term caloric restriction. Studies of lifetime caloric restriction in rodents have shown that such a regimen results in significant changes in collagen cross linking.\(^{25,26}\) Several morphological and biochemical studies of skin in patients with ALS have demonstrated (1) a significant negative correlation between the diameter of collagen fibrils and duration of illness;\(^{26}\) (2) decreased content of collagen;\(^{27}\) (3) alteration of cross linking of collagen;\(^{28}\) and (4) increased solubility of collagen.\(^{29}\) Thus these findings unique to ALS\(^{26-29}\) may be associated with the increased IGF-I immunoreactivity of skin in ALS shown in the present study.

We thank Dr David L. McIlwain, Professor of the Department of Cell and Molecular Physiology of the University of North Carolina at Chapel Hill, for his valuable comments and encouragement, and Mrs Sanae Fujii, Mr Akira Aso, and Mr Kenichi Hasegawa for their technical assistance.

---

Increased skin insulin-like growth factor I in amyotrophic lateral sclerosis


20 Turunen T, Toyokura Y. Amyotrophic lateral sclerosis and bedsores. Lancet 1976;i:862.


Increased expression of insulin-like growth factor I in skin in amyotrophic lateral sclerosis

Seiitsu Ono, Jianguo Hu, Takashi Imai, Natsue Shimizu, Mayumi Tsumura and Hachiro Nakagawa

*J Neurol Neurosurg Psychiatry* 2000 69: 199-203
doi: 10.1136/jnnp.69.2.199

Updated information and services can be found at:
http://jnnp.bmj.com/content/69/2/199

*These include:*

**References**
This article cites 23 articles, 5 of which you can access for free at:
http://jnnp.bmj.com/content/69/2/199#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1943)
- Motor neurone disease (302)
- Neuromuscular disease (1311)
- Spinal cord (542)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/